Diaceutics 2025 Non-Genomic Dataset

Diaceutics Inc/Diaceutics 2025 Non-Genomic Dataset is a Healthcare & Clinical data product listed on Snowflake Marketplace and indexed by The Alternative Data Encyclopedia.

Contains records related to lab data for non-genomic testing events from 2025-01-01 to 2025-09-17.

The lineage runs from IMS Health, founded in the mid-twentieth century, which turned prescription audits into a global industry and later merged into IQVIA. Broad EHR adoption in the 2010s created the modern real-world-data layer, and regulatory acceptance of real-world evidence expanded demand beyond commercial analytics into safety and label decisions. Newer entrants built daily-refreshed, health-system-owned datasets linking claims with clinical depth.

The signal

Clinical and health data at scale: aggregated medical claims, electronic health records, pharmacy transactions and trial-registry information organized around patients, providers and molecules. The signal measures real-world care flows — diagnoses, prescriptions, procedures — that anticipate pharmaceutical revenue and healthcare utilization before companies report them.

Prescription uptake leads recognized product revenue, so weekly script trajectories and new-start rates flag launch success or share loss quarters ahead of company reporting. Biotech desks price binary events with trial-status tracking, while shifts in treatment rates reveal payer-coverage changes and safety scares early. Hospital and procedure volumes feed service-line models for providers and device makers. Claims records carry diagnosis and procedure codes, drug fills, payer type and service dates; EHR layers add lab results, vitals, imaging metadata and clinical notes. Linkage produces longitudinal patient journeys across settings, while public trial registries contribute structured status timelines per study and indication. Derived products include molecule-level prescription shares, new-patient starts, persistence and adherence curves, and prescriber-level adoption metrics.

Data characteristics and access

Pricing: Paid subscription (Snowflake Marketplace).

Data arrives under agreements from payers, pharmacy-benefit managers, pharmacy switches and health-system EHR networks; some platforms are jointly owned by dozens of health systems contributing records updated daily. Records are de-identified to HIPAA safe-harbor or expert-determination standards and linked across sources through privacy-preserving tokenization. Aggregation enforces minimum cell sizes before delivery, and registry pipelines structure trial protocols into comparable status histories.

Caveats and compliance

Panels skew toward specific insurers, regions and health systems, so extrapolation to national volumes needs weighting. Coding practices vary across providers and change with reimbursement incentives. Claims finalize with weeks-to-months delay while EHR data arrive faster but capture different events, and suppression limits granularity for rare conditions.

This is the strictest privacy regime in alternative data: HIPAA governs US protected health information, GDPR treats health data as a special category in Europe, and state laws increasingly restrict consumer health data sales. Buyers should insist on documented de-identification, data-use agreements and audit trails.

Who uses this signal

Biotech and pharma equity analysts model drug-adoption curves and event probabilities; long/short funds monitor launch KPIs as leading indicators. Providers, payers and device makers consume the same data for benchmarking and market access.

Complementary signals

This kind of signal pairs naturally with adjacent categories of the encyclopedia:

Further reading